Effect of Venous Thrombotic Events on Overall Survival in Multiple Myeloma: Analysis of Thrombotic Events Occurring in E4A03A Randomized Trial of Lenalidomide Plus High-Dose Dexamethasone (RD) Versus Lenalidomide Plus Low-Dose Dexamethasone (Rd) in Newly Diagnosed Multiple Myeloma, a Trial Coordinated by the Eastern Cooperative Oncology Group (ECOG).

被引：0
|
作者：
Jacobus, Susanna [1 ]
Kumar, Shaji [2 ]
Callander, Natalie Scott [3 ]
Abonour, Rafat [4 ]
Fonseca, Rafael [5 ]
Siegel, David [6 ]
Greipp, Philip [2 ]
Rajkumar, S. Vincent [2 ]
机构：
[1] Dana Farber Canc Inst, Boston, MA 02115 USA
[2] Mayo Clin, Rochester, MN USA
[3] Univ Wisconsin, Madison, WI USA
[4] Indiana Univ Canc, Indianapolis, IN USA
[5] Mayo Clin, Scottsdale, AZ USA
[6] Hackensack Univ, Med Ctr, Hackensack, NJ USA
来源：
BLOOD | 2008年 / 112卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：613 / 614
页数：2
相关论文
共 50 条
  • [41] Health-related quality of life from the MM-003 trial of pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed and/or refractory multiple myeloma
    Song, Kevin W.
    Dimopoulos, Meletios A.
    Weisel, Katja C.
    Moreau, Philippe
    Palumbo, Antonio
    Belch, Andrew
    Schey, Stephen
    Sonneveld, Pieter
    Sternas, Lars
    Yu, Xin
    Amatya, Ramesh
    Monzini, Mara S.
    Zaki, Mohamed
    Jacques, Christian
    Miguel, Jesus San
    HAEMATOLOGICA, 2015, 100 (02) : E63 - E67
  • [42] IMPACT OF ECOG PERFORMANCE STATUS ON OVERALL SURVIVAL AND HRQOL IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS FROM THE MM-003 TRIAL OF POMALIDOMIDE plus LOW-DOSE DEXAMETHASONE (DEX) vs HIGH-DOSE DEX
    Weisel, K.
    San Miguel, J.
    Song, K.
    Delforge, M.
    Lewis, P.
    Yu, X.
    Zaki, M.
    Sternas, L.
    Dimopoulos, M.
    HAEMATOLOGICA, 2014, 99 : 518 - 518
  • [43] FIRST study: Updated overall survival (OS) in stem cell transplant (SCT)-ineligible newly diagnosed multiple myeloma (NDMM) patients (pts) treated with continuous lenalidomide plus low-dose dexamethasone (Rd) vs melphalan, prednisone, and thalidomide (MPT).
    Facon, Thierry
    Hulin, Cyrille
    Dimopoulos, Meletios A.
    Belch, Andrew
    Reece, Donna Ellen
    Catalano, John V.
    Pinto, Antonio
    Ludwig, Heinz
    Bahlis, Nizar J.
    Cavo, Michele
    Moreau, Philippe
    Qiu, Lugui
    LeBlanc, Richard
    Schots, Rik
    Rajkumar, S. Vincent
    Marek, Jennifer
    Chen, Guang
    Ervin-Haynes, Annette L.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [44] Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial
    San Miguel, Jesus
    Weisel, Katja
    Moreau, Philippe
    Lacy, Martha
    Song, Kevin
    Delforge, Michel
    Karlin, Lionel
    Goldschmidt, Hartmut
    Banos, Anne
    Oriol, Albert
    Alegre, Adrian
    Chen, Christine
    Cavo, Michele
    Garderet, Laurent
    Ivanova, Valentina
    Martinez-Lopez, Joaquin
    Belch, Andrew
    Palumbo, Antonio
    Schey, Stephen
    Sonneveld, Pieter
    Yu, Xin
    Sternas, Lars
    Jacques, Christian
    Zaki, Mohamed
    Dimopoulos, Meletios
    LANCET ONCOLOGY, 2013, 14 (11): : 1055 - 1066
  • [45] Outcome with lenalidomide plus dexamethasone followed by early autologous stem cell transplantation in patients with newly diagnosed multiple myeloma on the ECOG-ACRIN E4A03 randomized clinical trial: long-term follow-up
    Biran, N.
    Jacobus, S.
    Vesole, D. H.
    Callander, N. S.
    Fonseca, R.
    Williams, M. E.
    Abonour, R.
    Katz, M. S.
    Rajkumar, S. V.
    Greipp, P. R.
    Siegel, D. S.
    BLOOD CANCER JOURNAL, 2016, 6 : e466 - e466
  • [46] Outcome with lenalidomide plus dexamethasone followed by early autologous stem cell transplantation in patients with newly diagnosed multiple myeloma on the ECOG-ACRIN E4A03 randomized clinical trial: long-term follow-up
    N Biran
    S Jacobus
    D H Vesole
    N S Callander
    R Fonseca
    M E Williams
    R Abonour
    M S Katz
    S V Rajkumar
    P R Greipp
    D S Siegel
    Blood Cancer Journal, 2016, 6 : e466 - e466
  • [47] Lenalidomide and low-dose dexamethasone (Rd) versus bortezomib, melphalan, prednisone (VMP) in elderly newly diagnosed multiple myeloma patients: A comparison of two prospective trials (vol 92, pg 244, 2017)
    Gentile
    AMERICAN JOURNAL OF HEMATOLOGY, 2020, 95 (04) : 449 - 450
  • [48] EFFECT OF LENALIDOMIDE PLUS LOW-DOSE DEXAMETHASONE TREATMENT UNTIL PROGRESSION ON HEALTH-RELATED QUALITY OF LIFE OVER TIME IN TRANSPLANT-INELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA
    Vogl, D. T.
    Delforge, M.
    Song, K.
    Guo, S.
    Gibson, C. J.
    Ervin-Haynes, A.
    Facon, T.
    HAEMATOLOGICA, 2016, 101 : 145 - 145
  • [49] Effect of Treatment with Lenalidomide Plus Low-Dose Dexamethasone Until Progression on Health-Related Quality of Life Over Time in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma
    Vogl, Dan T.
    Delforge, Michel
    Song, Kevin
    Guo, Shien
    Gibson, Craig J.
    Ervin-Haynes, Annette
    Facon, Thierry
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 (01): : E87 - E87
  • [50] CYTOGENETICS AND LONG-TERM SURVIVAL IN MM-003, A PHASE 3 TRIAL OF POMALIDOMIDE plus LOW-DOSE DEXAMETHASONE VS. HIGH-DOSE DEXAMETHASONE IN REFRACTORY OR RELAPSED AND REFRACTORY MULTIPLE MYELOMA
    Dimopoulos, M. A.
    Weisel, K.
    Song, K. W.
    Delforge, M.
    Karlin, L.
    Goldschmidt, H.
    Moreau, P.
    Banos, A.
    Oriol, A.
    Garderet, L.
    Cavo, M.
    Ivanova, V.
    Alegre, A.
    Martinez-Lopez, J.
    Chen, C. I.
    Spencer, A.
    Knop, S.
    Bahlis, N. J.
    Renner, C.
    Yu, X.
    Hong, K.
    Sternas, L.
    Jacques, C.
    Zaki, M. H.
    San Miguel, J. F.
    HAEMATOLOGICA, 2014, 99 : 365 - 365
12345